ABSTRACT
<p><b>OBJECTIVE</b>To probe the risk of colorectal polyp, colon and rectal carcinoma and the intake of NSAIDs.</p><p><b>METHODS</b>Case-control study participants were from patients who underwent colonoscopy at different hospitals, the persons with the above disease was as cases, and those without the above diseases was as controls. Use of NSAIDs was assessed by interviewing the participants with a questionnaire which include a list of NSAIDs and related dietary and life style factors and family history.</p><p><b>RESULTS</b>There are 37 cases of colorectal polyp, 105 cases of colon carcinoma and 142 cases of rectal carcinoma and 66 controls. Adjusted for potential confounders, the risk of colorectal polyposis, colon carcinoma and rectal carcinoma were markedly reduced by NSAIDs. The OR values were 0.21 (95% CI 0.07-0.65, P = 0.007), 0.13 (95% CI 0.05-0.35, P < 0.001), 0.15 (95% CI 0.11-0.58, P < 0.001) respectively. The risk of the above diseases were also reduced markedly by aspirin, the OR values were 0.265 (95% CI 0.07-0.96, P = 0.044), 0.10 (95% CI 0.03-0.35, P < 0.001), 0.15 (95% CI 0.04-0.49, P = 0.002) respectively. The risk of colon carcinoma was also reduced by profen, with the OR being 0.11 (95% CI 0.02-0.64, P = 0.014).</p><p><b>CONCLUSIONS</b>Aspirin and other NSAIDs could reduced the risk of colorectal polyp, colon carcinoma and rectal carcinoma markedly. Aspirin was the most prospective chemopreventive agents for colorectal polyp, colon and rectal carcinoma for its capability of reducing the risk of cardio-cerebral vascular disease as well.</p>
Subject(s)
Adult , Female , Humans , Male , Middle Aged , Anti-Inflammatory Agents, Non-Steroidal , Therapeutic Uses , Aspirin , Therapeutic Uses , Colorectal Neoplasms , Ibuprofen , Therapeutic Uses , Logistic Models , Piroxicam , Therapeutic Uses , Polyps , Rectal Neoplasms , Risk Factors , Sulindac , Therapeutic Uses , Time FactorsABSTRACT
AIM To investigate the effects of piroxicam on transplanted Sarcoma S180 and the expression of COX 2,VEGF,FGF 2 and microvessel density (MVD) in tumor tissue METHODS Kunming mice were randomizedly divided into control group, FT207 positive group and 5, 2 5, 1 mg?kg -1 piroxicam groups One day after inoculation of 0 2 ml S180 cell suspension, FT207 and piroxicam were given by gastric intubation for 9 days The inhibitory rate on S180 was calculated routinely The expression of COX 2,VEGF,FGF 2 and MVD was detected by immunohistochemistry RESULTS The growth of S180 was significantly inhibited by piroxicam at the doses of 5, 2 5, 1 mg?kg -1 with the inhibitory rate of 31 4%,40 7% and 34 9% respectively The expression of COX 2 in the tumor tissue was also inhibited by piroxicam. Accordingly the expression of VEGF,FGF 2 and MVD was markedly inhibited in dose dependent manner by piroxicam CONCLUSIONS The results suggest that piroxicam has inhibitory effects on S180,and it also decreases the expression of COX 2 in tumor tissue. There is a relation ship between the expression of COX 2 and angiogenesis related factor Antiangiogenesis may be another mechanism for piroxicam to exert its chemopreventive and treatment effects.